The journey of the data point is no longer linear, as advanced digital innovations are now employed throughout all the phases of drug development, agreed a panel of data scientists and experts.
On the third day of the 2022 BIO International Convention in San Diego, California, data scientists gathered for a panel session titled, “The New Journey of a Data Point: Digital Innovation for a Powerful Purpose, where they discussed the future of the data journey.
Sponsored by Bristol Myers Squibb, the panel was moderated by Venkat Sethuraman, Senior VP of Global Biometrics and Data Sciences at Bristol Myers Squibb. She was joined by:
- Miruna Sasu, CEO of COTA
- Michael Krams, Chief Quantitative Medicine Officer at Exscentia
- Vikram Chaudhery, Partner at Genoa
- Hamish Wright, VP of Translational Science at Schrödinger
Keeping patients at the center is one of the ways to integrate all the information and make better decisions, from a clinical perspective, or from a target’s perspective.
“There is a way for all of us to share information, bring together all the groups responsible for generating this data so we can best utilize it, and create relevant revelations for our patients,” Sethuraman said.
